# US 2023/0265124 A1 · Oxytocin analogues and methods for using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265124 A1
- Document ID: US20230265124A1
- Status: Published application
- Kind: A1
- Application number: 18/006,841
- Filed: 2021-07-27
- Published: 2023-08-24
- Earliest claimed: 2020-07-27
- Assignees: Az. Bd. of Reg. on Behalf of the Univ. of Arizona
- Applicants: Az. Bd. of Reg. on Behalf of the Univ. of Arizona
- Inventors: Robin L. Polt; Lajos Z. Szabo; John M. Streicher; Parthasaradhireddy Tanguturi
- Web page: https://patentgrep.com/patent/US20230265124A1

## CPC

- C07K 7/16: Oxytocins; Vasopressins; Related peptides
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides cyclic oligopeptides and methods for using the same. The cyclic oligopeptides of the invention are analogues of oxytocin wherein the disulfide linkage between Cys1 and Cys2 are replaced with a more stable amide bond. The cyclic oligopeptides of the invention can also include a glycoside to increase blood-brain barrier penetration. In particular, the cyclic oligopeptide of the invention is of the formula: (A) (SEQ ID NO:2) where one of AA1 or AA6 is an amino acid having a carboxylic acid side-chain and the other is a carboxylic acid having an amine functional group on the side-chain such that X1 and X2 together form an amide bond; and each of AA2-AA5 and AA7-AA11 is independently natural or unnatural amino acids with at least one, typically at least two, often at least three, more often at least four, and most often at least five of which is an amino acid that is present in the corresponding position of oxytocin.

## Claims

### Claim 1

A cyclic oligopeptide of the formula:
or a pharmaceutically acceptable salt thereof, a prodrug thereof, or a solvate thereof, wherein
one of AA1 or AA6 is an amino acid having a carboxylate side-chain functional group and the other is an amino acid having an amine side-chain functional group such that X1 and X2 together form an amide bond;
AA3 is Phe or Ile;
AA8 is Arg, Leu, or Aib;
each of AA9 and AA10 is independently Gly, Ser, Cys, Thr or an analog thereof, or absent; and
AA11 is Gly, Ser, Cys, Thr or an analog thereof, and wherein
at least one of the amino acid residues is optionally glycosylated.

### Claim 2 (depends on 1)

The cyclic oligopeptide of claim 1, wherein one of AA1 and AA6 is aspartic acid or glutamic acid and the other is lysine, ornithine, diaminobutyric acid (DABA), or 2,3-diaminopropionic acid (DAPA).

### Claim 3 (depends on 1)

The cyclic oligopeptide of claim 1, wherein at least one of the amino acid residues is glycosylated.

### Claim 4 (depends on 3)

The cyclic oligopeptide of claim 3, wherein said amino acid is glycosylated with a monosaccharide or a disaccharide.

### Claim 5 (depends on 4)

The cyclic oligopeptide of claim 4, wherein said monosaccharide comprises allose, altrose, glucose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, psicose, fructose, sorbose, tagatose, ribulose, or xylulose.

### Claim 6 (depends on 4)

The cyclic oligopeptide of claim 4, wherein said disaccharide comprises sucrose, lactose, maltose, trehalose, cellobiose, lactulose, chitobiose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, psicose, fructose, sorbose, tagatose, ribulose, or xylulose.

### Claim 7 (depends on 4)

The cyclic oligopeptide of claim 4, wherein said monosaccharide is an (L)-isomer.

### Claim 8 (depends on 4)

The cyclic oligopeptide of claim 4, wherein said monosaccharide is a (D)-isomer.

### Claim 9 (depends on 4)

The cyclic oligopeptide of claim 4, wherein at least one monosaccharide unit of said disaccharide is an (L)-isomer.

### Claim 10 (depends on 1)

The cyclic oligopeptide of claim 1, wherein at least one of AA10 and AA11 is serine, threonine or an analog thereof.

### Claim 11 (depends on 10)

The cyclic oligopeptide of claim 10, wherein at least one of AA10 and AA11 is glycosylated serine.

### Claim 12 (depends on 1)

The cyclic oligopeptide of claim 1, wherein one of AA1 or AA6 is an amino acid having a carboxylate side-chain and the other is 2,3-diaminopropionic acid.

### Claim 13 (depends on 12)

The cyclic oligopeptide of claim 12, wherein said amino acid having a carboxylate side-chain is aspartic acid or glutamic acid.

### Claim 14 (depends on 1)

The cyclic oligopeptide of claim 1, wherein AA8 is Leu or Aib.

### Claim 15 (depends on 1)

The cyclic oligopeptide of claim 1, wherein AA11 is Gly or glycosylated Ser.

### Claim 16 (depends on 15)

The cyclic oligopeptide of claim 15, wherein AA9 is absent.

### Claim 17 (depends on 16)

The cyclic oligopeptide of claim 16, wherein AA10 is Gly or glycosylated Ser.

### Claim 18

A method for treating a clinical condition to a subject in need of such a treatment, said method comprising administering to said subject a therapeutically effective amount of a cyclic oligopeptide of the formula:
or a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or a combination thereof, wherein
one of AA1 or AA6 is an amino acid having a carboxylate side-chain functional group and the other is an amino acid having an amine side-chain functional group such that X1 and X2 together form an amide bond;
AA3 is Phe or Ile;
AA8 is Arg, Leu, or Aib;
each of AA9 and AA10 is independently Gly, Ser, cysteine, threonine or an analog thereof, or absent; and
AA11 is Gly, Ser, cysteine, threonine or an analog thereof,
wherein at least one of the amino acid residues is optionally glycosylated, and wherein
said clinical condition is selected from the group consisting of chronic pain, acute pain, opioid addiction, alcohol addiction, Autism Spectrum Disorders, Asperger’s Syndrome, and a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein at least one of the amino acid residues is glycosylated.

### Claim 20 (depends on 19)

The method of claim 19, wherein said glycosylated amino acid residue is serine.
